Emerging therapeutic options for advanced enteropancreatic neuroendocrine tumors

Bibliography

• Rehfeld JF. The new biology of gastrointestinal hormones. Physiol Rev 1998;78:1087-108
   PubMed Web of Science ®Google Scholar
• Modlin IM, Shapiro MD, Kidd M, Siegfried Oberndorfer and the evolution of carcinoid disease. Arch Surg 2007;142:187-97
   PubMedGoogle Scholar
• Kloppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann. N. Y. Acad. Sci 2004;1014:13-27
   PubMed Web of Science ®Google Scholar
• Ehehalt F, Saeger HD, Schmidt CM, Neuroendocrine tumors of the pancreas. Oncologist 2009;14:456-67
   PubMed Web of Science ®Google Scholar
• Bosman F, Carneiro F, Hruban R, Theise N. editors. WHO Classification of Tumours of the Digestive System. IARC Press; Lyon, France: 2010
   Google Scholar
• Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97:934-59
   PubMed Web of Science ®Google Scholar
• Delaunoit T, Neczyporenko F, Rubin J, Medical management of pancreatic neuroendocrine tumors. Am J Gastroenterol 2008;103:475-83
   PubMed Web of Science ®Google Scholar
• Yao JC, Hassan M, Phan A, One hundred years after ‘carcinoid’: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-72
   PubMed Web of Science ®Google Scholar
• Phan AT, Yao JC. Neuroendocrine tumors: novel approaches in the age of targeted therapy. Oncology (Huntingt) 2008;22:1617-23. discussion 1623-1624, 1629
   PubMedGoogle Scholar
• Ghevariya V, Malieckal A, Ghevariya N, Carcinoid tumors of the gastrointestinal tract. South Med J 2009;102:1032-40
   PubMedGoogle Scholar
• Halfdanarson TR, Rabe KG, Rubin J, Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol 2008;19:1727-33
   PubMed Web of Science ®Google Scholar
• Modlin IM, Latich I, Kidd M, Therapeutic options for gastrointestinal carcinoids. Clin Gastroenterol Hepatol 2006;4:526-47
   PubMed Web of Science ®Google Scholar
• Ramage JK, Davies AHG, Ardill J, Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 2005;54(Suppl):1-16
   PubMedGoogle Scholar
• Goldin SB, Aston J, Wahi MM. Sporadically occurring functional pancreatic endocrine tumors: review of recent literature. Curr Opin Oncol 2008;20:25-33
   PubMedGoogle Scholar
• Grant CS. Insulinoma. Best Pract Res Clin Gastroenterol 2005;19:783-98
   PubMed Web of Science ®Google Scholar
• Tucker ON, Crotty PL, Conlon KC. The management of insulinoma. Br J Surg 2006;93:264-75
   PubMed Web of Science ®Google Scholar
• Kulke MH, Bendell J, Kvols L, Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors. J Hematol Oncol 2011;4:29
   PubMed Web of Science ®Google Scholar
• Katayama A, Iseda I, Tone A, The usefulness of super-selective computed tomography angiography (CTA) for diagnosing and localizing a small insulinoma. Intern Med 2010;49:1983-6
   PubMedGoogle Scholar
• Ramanathan RK, Cnaan A, Hahn RG, Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol 2001;12:1139-43
   PubMed Web of Science ®Google Scholar
• Kolby L, Persson G, Franzen S, Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg 2003;90:687-93
   PubMed Web of Science ®Google Scholar
• Dahan L, Bonnetain F, Rougier P, Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710. Endocr Relat Cancer 2009;16:1351-61
   PubMed Web of Science ®Google Scholar
• Moertel CG, Hanley JA, Johnson LA. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 1980;303:1189-94
   PubMed Web of Science ®Google Scholar
• Moertel CG, Lefkopoulo M, Lipsitz S, Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992;326:519-23
   PubMed Web of Science ®Google Scholar
• Bajetta E, Catena L, Procopio G, Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol 2007;59:637-42
   PubMed Web of Science ®Google Scholar
• Fjallskog MH, Janson ET, Falkmer UG, Treatment with combined streptozotocin and liposomal doxorubicin in metastatic endocrine pancreatic tumors. Neuroendocrinology 2008;88:53-8
   PubMed Web of Science ®Google Scholar
• Cassier PA, Walter T, Eymard B, Gemcitabine and oxaliplatin combination chemotherapy for metastatic well-differentiated neuroendocrine carcinomas: a single-center experience. Cancer 2009;115:3392-9
   PubMed Web of Science ®Google Scholar
• Moertel CG, Kvols LK, O'Connell MJ, Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991;68:227-32
   PubMed Web of Science ®Google Scholar
• Mitry E, Baudin E, Ducreux M, Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 1999;81:1351-5
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Spigel DR, Litchy S, Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a minnie pearl cancer research network study. J Clin Oncol 2006;24:3548-54
   PubMed Web of Science ®Google Scholar
• Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999;20:157-98
   PubMed Web of Science ®Google Scholar
• De Herder WW, Hofland LJ, van der Lely AJ, Somatostatin receptors in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 2003;10:451-8
   PubMed Web of Science ®Google Scholar
• Modlin IM, Pavel M, Kidd M, Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 2010;31:169-88
   PubMed Web of Science ®Google Scholar
• Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 2003;24:28-47
   PubMed Web of Science ®Google Scholar
• Bruns C, Lewis I, Briner U, SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002;146:707-16
   PubMed Web of Science ®Google Scholar
• Safety and efficacy of pasireotide long acting release vs. octreotide long acting release in patients with metastatic carcinoid disease. Available from http://www.clinicaltrial.gov/; Identifier: NCT00690430
   Google Scholar
• Rinke A, Muller HH, Schade-Brittinger C, Placebo-controlled, doubleblind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009;27:4656-63
   PubMed Web of Science ®Google Scholar
• Aparicio T, Ducreux M, Baudin E, Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer 2001;37:1014-19
   PubMed Web of Science ®Google Scholar
• Auernhammer CJ, Goke B. Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin. Gut 2011;60:1009-21
   PubMedGoogle Scholar
• Fazio N, Cinieri S, Lorizzo K, Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas. Cancer Treat Rev 2010;36(Suppl):S87-94
   Google Scholar
• Anthony CT, Bastidas JG, Thomson JL, A study of pipeline drugs in neuroendocrine tumors. J Gastrointest Cancer 2011; [Epub ahead of print]
   Google Scholar
• Raymond E, Dahan L, Raoul JL, Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501-13
   PubMed Web of Science ®Google Scholar
• Yao JC, Phan A, Hoff PM, Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment Phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008;26:1316-23
   PubMed Web of Science ®Google Scholar
• Kulke MH, Stuart K, Earle CC, A Phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. J Clin Oncol 2006;24(Suppl):4044S
   PubMedGoogle Scholar
• Dasanu CA, Clark BA III, Alexandrescu DT. mTOR-blocking agents in advanced renal cancer: an emerging therapeutic option. Expert Opin Investig Drugs 2009;18:175-87
   PubMed Web of Science ®Google Scholar
• Garcia JA, Danielpour D. Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther 2008;7:1347-54
   PubMed Web of Science ®Google Scholar
• Smolewski P. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs 2006;17:487-94
   PubMed Web of Science ®Google Scholar
• Yao JC, Shah MH, Ito T, Everolimus for Advanced Pancreatic Neuroendocrine Tumors. N Engl J Med 2011;364:514-23
   PubMed Web of Science ®Google Scholar
• Pavel ME, Hainsworth JD, Baudin E, Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, Phase III study. Lancet 2011;378:2005-12
   PubMed Web of Science ®Google Scholar
• Yao JC, Hainsworth D, Baudin E, Everolimus plus octreotide LAR (E + O) versus placebo plus octreotide LAR (P + O) in patients with advanced neuroendocrine tumors (NET): updated results of a randomized, double-blind, placebo-controlled, multicenter phase III trial (RADIANT-2). Gastrointest Cancer Symp 2011;abstract 159
   Google Scholar
• Yao JC, Lombard-Bohas C, Baudin E, Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010;28:69-76
   PubMed Web of Science ®Google Scholar
• Strosberg JR, Fine RL, Choi J, First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011;117:268-75
   PubMed Web of Science ®Google Scholar
• van Essen M, Krenning EP, Kam BL, Peptide-receptor radionuclide therapy for endocrine tumors. Nat Rev Endocrinol 2009;5:382-93
   PubMed Web of Science ®Google Scholar
• Van Essen M, Krenning EP, De Jong M, Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol 2007;46:723-34
   PubMed Web of Science ®Google Scholar
• Forrer F, Valkema R, Kwekkeboom DJ, Neuroendocrine tumors. Peptide receptor radionuclide therapy. Best Pract Res Clin Endocrinol Metab 2007;21:111-29
   PubMed Web of Science ®Google Scholar
• Imhof A, Brunner P, Marincek N, Response, Survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2010;33:abstract 7873
   Google Scholar
• Kwekkeboom DJ, Kam BL, van Essen M, Somatostatinreceptor- based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 2010;17:R53-73
   PubMed Web of Science ®Google Scholar
• Kwekkeboom DJ, van de Herder W, Kam BL, Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3] Octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124-30
   PubMed Web of Science ®Google Scholar
• Wood JM, Bold G, Buchdunger E, PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000;60:2178-89
   PubMed Web of Science ®Google Scholar
• Anthony L, Chester M, Michael S, Phase II open-label clinical trial of vatalanib (PTK/ZK) in patients with progressive neuroendocrine cancer. J Clin Oncol 2008;26: abstract 14624
   Google Scholar
• Kulke MH, Stuart K, Enzinger PC, Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006;24:401-6
   PubMed Web of Science ®Google Scholar
• Tolcher A, Rothenberg M, Rodon J, A phase I pharmakinetic and pharmacodynamic study of AMG 479, a fully monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-IR) in advanced solid tumors. J Clin Oncol 2007;25:3002
   Google Scholar
• Yao JC, Zhang JX, Rashid A, Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res 2007;13:234-40
   PubMed Web of Science ®Google Scholar
• Hobday T, Rubin J, Holen K, MC044h, a Phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a Phase II Consortium (P2C) study. 2007 ASCO Annual Meeting, Journal ofClinical Oncology, 2007. ASCO Annu Meeting Proc Part I 2007;25(18 Suppl 20):4504
   Google Scholar
• Chan J, Ryan D, Fuchs CS, Updated results of a Phase I study of pasireotide (SOM230) in combination with everolimus (RAD001) in patients (pts) with advanced neuroendocrine tumors (NET). 2011 ASCO Annual Meeting. J Clin Oncol 2011;29(Suppl):abstract 4120
   Google Scholar
• Kvols L, Wiedenmann B, Oberg K, Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: Results of a Phase II study. Gastrointest Cancer Symp 2006;abstract 171
   Google Scholar
• Castellano DE, Capdevila J, Salazar R, Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumor: A Phase II study of the Spanish Neuroendocrine Tumor Group (GETNE0801). 2011 ASCO Annual Meeting. J Clin Oncol 2011;29(Suppl):abstract 4113
   Google Scholar